Apolex SRL
Apolex reported total assets of €1.47m at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Aug 2026).
The score of Apolex shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +93 % Total assets +29 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apolex's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Aug 2026
- Year ended 31 Dec 2024filed on 16 Oct 2025
- Year ended 31 Dec 2023filed on 15 Jul 2024
- Year ended 31 Dec 2022filed on 29 Aug 2023
- Year ended 31 Dec 2021filed on 02 Sep 2022
Apolex's financial analysis
- Solvency90.2%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apolex
Apolex's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0828.111.170
- VAT number
- BE0828111170
- Peppol
- Registered · 0208:0828111170 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 28 Jul 2010
- Registered office
- 9260 Wichelen
- Latest accounts
- 2025 · filed on 28 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apolex (SRL) has been based in Wichelen since 2010, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 229,606 € and equity of €1.32m; its revenue is not published. Its solvency stands at 90.2%, above the median of its sector (44.0%).
Companies similar to Apolex
Companies in the same business, of comparable size and area, outside its group.
- DE Spiegeleere - Discart Retail sale of pharmaceutical products Braine-l'Alleud · balance sheet €1.36m
- Decopharma Retail sale of pharmaceutical products Sint-Niklaas · balance sheet €1.36m
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Verbifarma Retail sale of pharmaceutical products Pittem · balance sheet €1.47m
- Escapharm Retail sale of pharmaceutical products Kluisbergen · balance sheet €1.46m
- Apotheek DE Wilde ZEE Retail sale of pharmaceutical products Antwerp · balance sheet €1.48m
- Vanschoonbeek Farma Retail sale of pharmaceutical products Bekkevoort · balance sheet €1.50m
- VDV Pharma Retail sale of pharmaceutical products Schaerbeek · balance sheet €1.52m
Frequently asked questions about Apolex
What is the revenue of Apolex?
Apolex files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apolex?
In Belgium, the VAT number is the company number prefixed with BE: BE0828111170 for Apolex, if the company is VAT-registered. Its company number (CBE) is 0828.111.170.
Where is the registered office of Apolex?
According to the CBE register, the registered office of Apolex is in 9260 Wichelen.
What is the equity of Apolex?
At the close of the 2025 financial year, the equity of Apolex amounts to 1,323,431 €, a solvency of 90.2% of total assets.
Who manages Apolex?
The register lists 1 active mandates at Apolex. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apolex
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →